Erzofri Extended-Release
Payments companies reported to CMS as associated with Erzofri Extended-Release. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Erzofri Extended-Release, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Erzofri Extended-Release
These are the largest totals companies reported as associated with Erzofri Extended-Release. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Justin Faden | Cherry Hill, NJ | Psychiatry | $28,598.32 |
| Peter Weiden | Chicago, IL | Psychiatry | $27,189.75 |
| Leslie Citrome | Pomona, NY | Psychiatry | $24,008.33 |
| Frank Chen | Houston, TX | Psychiatry | $18,462.86 |
| Manish Zinzuvadia | New York, NY | Psychiatry | $15,323.14 |
| Gustavo Alva | Orange, CA | Psychiatry | $14,548.85 |
| Desiree Matthews | Charlotte, NC | Psychiatric/Mental Health (Nurse Practitioner) | $11,523.01 |
| Hara Oyedeji | Owings Mills, MD | Psychiatric/Mental Health (Nurse Practitioner) | $11,276.88 |
| Brooke Kempf | Terre Haute, IN | Psychiatric/Mental Health (Nurse Practitioner) | $10,632.74 |
| Jonathan Meyer | San Diego, CA | Psychiatry | $9,900.00 |
Prescribed Erzofri Extended-Release?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.